Zimmer Biomet Holdings, Inc. (ZBH) SEC Filings & Earnings Calls
EquiReason read 15 Zimmer Biomet Holdings, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-08 — Zimmer Biomet announced restructuring: Kevin Thornal (Group President) departing Sep 30, 2026; promotions of Gary Campbell (President, Americas), Brian Hatcher (President, Recon, S.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 18.8B
- P/E TTM
- 23.9
- Dividend yield
- 1.0%
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
8 Sep 20268-K · 5.02, 7.01Zimmer Biomet announced restructuring: Kevin Thornal (Group President) departing Sep 30, 2026; promotions of Gary Campbell (President, Americas), Brian Hatcher (President, Recon, S.E.T., CMFT, Neuro and Biosurgery), Bradley Kessler (Presideopen
Guidance
Company reiterates full-year 2026 financial outlook
Risks flagged
Departure of Group President; restructuring may cause short-term disruption
“Kevin Thornal departing September 30, 2026”
5 Aug 202610-QZimmer Biomet reported Q2 2026 net sales of $2,177.0 million, up 4.8% YoY, and net earnings of $198.3 million, up 29.8% YoY.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q2-2026 | $2.18B | +5% y/y |
| Net Earnings of Zimmer Biomet Holdings, Inc. · Q2-2026 | $198M | +30% y/y |
| Net cash provided by operating activities · H1-2026 | $807M | +6% y/y |
| Knees · Knees · Q2-2026 | $829M | +0% y/y |
| Hips · Hips · Q2-2026 | $563M | +5% y/y |
| S.E.T. · S.E.T. · Q2-2026 | $586M | +6% y/y |
| Technology & Data, Bone Cement and Surgical · Technology & Data, Bone Cement and Surgical · Q2-2026 | $199M | +21% y/y |
| United States · United States · Q2-2026 | $1.24B | +6% y/y |
| International · International · Q2-2026 | $937M | +4% y/y |
Risks flagged
Goodwill Impairment Risk
“our Global Foot and Ankle reporting unit's estimated fair value only exceeded its carrying value by approximately 5 percent.” · word for word
Integration Risk from Acquisitions
“The Monogram robotic technologies are currently not commercialized and therefore have been recognized as an IPR&D intangible asset.” · word for word
Debt Refinancing Risk
“Current portion of long-term debt increased to $1,201.5 million from $587.1 million at year-end 2025.”
5 Aug 20268-K · 2.02Net Sales $2.18B (+5% y/y); Diluted Earnings Per Share $1.03 (+34% y/y); Adjusted Diluted EPS $2.07 (+0% y/y); Guidance: Reported revenue change raised to 3.9%-4.9% from 2.5%-4.5%; adjusted EPS raised to $8.47-$8.59 from $8.40-$8.55earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q2-2026 | $2.18B | +5% y/y |
| Diluted Earnings Per Share · Q2-2026 | $1.03 | +34% y/y |
| Adjusted Diluted EPS · Q2-2026 | $2.07 | 0% y/y |
| Operating Cash Flow · Q2-2026 | $448M | |
| Free Cash Flow · Q2-2026 | $308M | |
| Knees Net Sales · Knees · Q2-2026 | $829M | +0% y/y |
| Hips Net Sales · Hips · Q2-2026 | $563M | +5% y/y |
| S.E.T. Net Sales · S.E.T. · Q2-2026 | $586M | +6% y/y |
| Technology & Data, Bone Cement and Surgical Net Sales · Technology & Data, Bone Cement and Surgical · Q2-2026 | $199M | +21% y/y |
Guidance
Reported revenue change raised to 3.9%-4.9% from 2.5%-4.5%; adjusted EPS raised to $8.47-$8.59 from $8.40-$8.55
Raised FY2026 revenue and adjusted EPS guidance, citing strong first half and healthy markets.
Risks flagged
Knees segment growth flat (+0.4%), indicating potential market saturation or competitive pressure.
“Knees 828.9 +0.4%”
Adjusted EPS flat YoY despite revenue growth suggests cost pressures or mix headwinds.
“adjusted diluted earnings per share were $2.07, consistent with the prior year period”
1 May 202610-QNet Sales $2.09B (+9% y/y); Net Earnings of Zimmer Biomet Holdings, Inc. $238M (+31% y/y); Operating Cash Flow $359M (-6% y/y)open
Figures in the filing · each found in the filing text
| Net Sales · Q1-2026 | $2.09B | +9% y/y |
| Net Earnings of Zimmer Biomet Holdings, Inc. · Q1-2026 | $238M | +31% y/y |
| Operating Cash Flow · Q1-2026 | $359M | -6% y/y |
| Free Cash Flow · Q1-2026 | $246M | |
| Knees Revenue · Knees · Q1-2026 | $829M | +5% y/y |
| Hips Revenue · Hips · Q1-2026 | $524M | +6% y/y |
| S.E.T. Revenue · S.E.T. · Q1-2026 | $562M | +20% y/y |
| Technology & Data, Bone Cement and Surgical Revenue · Technology & Data, Bone Cement and Surgical · Q1-2026 | $172M | +15% y/y |
| United States Revenue · United States · Q1-2026 | $1.21B | +9% y/y |
| International Revenue · International · Q1-2026 | $877M | +10% y/y |
Risks flagged
Goodwill impairment risk for Global Foot and Ankle reporting unit
“Global Foot and Ankle reporting unit's estimated fair value only exceeded its carrying value by approximately 5 percent.” · word for word
Integration risk from recent acquisitions (Paragon 28, Monogram)
“We completed the acquisition of Paragon 28 in April 2025 and Monogram in October 2025; purchase price allocations are still preliminary.”
Restructuring execution risk
“2025 Restructuring Plan expected to result in total pre-tax charges of approximately $155 million by end of 2027.”
28 Apr 20268-K · 2.02Net Sales $2.09B (+9% y/y); Net Earnings $238M; Adjusted Net Earnings $409M; Guidance: Adjusted EPS raised from $8.30-$8.45 to $8.40-$8.55; free cash flow expectations raisedearningsopen
Figures in the filing · each found in the filing text
| Net Sales · total · Q1-2026 | $2.09B | +9% y/y |
| Net Earnings · total · Q1-2026 | $238M | |
| Adjusted Net Earnings · total · Q1-2026 | $409M | |
| Diluted EPS · total · Q1-2026 | $1.22 | +34% y/y |
| Adjusted Diluted EPS · total · Q1-2026 | $2.09 | +16% y/y |
| Operating Cash Flow · total · Q1-2026 | $359M | |
| Free Cash Flow · total · Q1-2026 | $246M | |
| U.S. Net Sales · United States · Q1-2026 | $1.21B | +9% y/y |
| International Net Sales · International · Q1-2026 | $877M | +10% y/y |
| Knees Net Sales · Knees · Q1-2026 | $829M | +5% y/y |
Guidance
Adjusted EPS raised from $8.30-$8.45 to $8.40-$8.55; free cash flow expectations raised
Full-year 2026 adjusted EPS guidance raised by $0.10 at midpoint; revenue guidance unchanged; free cash flow expectations raised. CEO cites healthy end markets and product momentum.
Risks flagged
Foreign exchange headwind remains, though guidance includes +0.5% FX impact.
“Foreign Currency Exchange Impact +0.5%” · word for word
Organic constant currency growth of only 2.9% suggests underlying demand may be modest despite reported growth boosted by acquisitions and FX.
“Organic constant currency % Change 2.9%”
Paragon 28 acquisition integration risk; acquisition contributed ~100bps to growth.
“Excludes the projected impact of the Paragon 28 acquisition through the one-year anniversary of the acquisition date, which is estimated to be approximately 100bps.” · word for word
28 Apr 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)open
Risks flagged
Key executive departure may disrupt financial operations and strategy execution.
“CFO resignation effective April 28, 2026; search for permanent CFO underway.”
1 Apr 2026DEF 14AAnnual proxy statement disclosing executive compensation structure, governance practices, and shareholder proposals.open
Figures in the filing · each found in the filing text
| Constant Currency Revenue · FY2025 | $8.04B | |
| Adjusted Operating Profit · FY2025 | $2.26B | |
| Free Cash Flow · FY2025 | $1.17B |
Risks flagged
Product liability litigation
“As of October 2025, individual lawsuits are still being filed against Zimmer Biomet for injuries related to its Biomet M2a Magnum and Zimmer Biomet CPT Hip System implants.” · word for word
Operational/IT disruption
“In September 2025, Zimmer Biomet sued its IT provider, Deloitte, for $172 million, alleging fraud and breach of contract.” · word for word
Tariff headwinds
“In early May 2025, Zimmer Biomet lowered its full-year adjusted profit forecast, citing headwinds from tariffs and the Paragon 28 acquisition.” · word for word
20 Feb 202610-KNet Sales $8.23B (+7% y/y); Net Earnings $705M (-22% y/y); Operating Cash Flow $1.70B (+13% y/y); Guidance: FY2026 net sales growth guided 2.5%-4.5%; operating profit expected to increaseopen
Figures in the filing · each found in the filing text
| Net Sales · FY2025 | $8.23B | +7% y/y |
| Net Earnings · FY2025 | $705M | -22% y/y |
| Operating Cash Flow · FY2025 | $1.70B | +13% y/y |
| Gross Margin · FY2025 | 61.6% | |
| Operating Profit Margin · FY2025 | 13.3% | |
| Knees Net Sales · Knees · FY2025 | $3.32B | +5% y/y |
| Hips Net Sales · Hips · FY2025 | $2.09B | +5% y/y |
| S.E.T. Net Sales · S.E.T. · FY2025 | $2.15B | +15% y/y |
| Technology & Data, Bone Cement and Surgical Net Sales · Technology & Data, Bone Cement and Surgical · FY2025 | $666M | +4% y/y |
| Americas Segment Profit · Americas · FY2025 | $2.65B | +3% y/y |
Guidance
FY2026 net sales growth guided 2.5%-4.5%; operating profit expected to increase
2026 guidance: net sales growth 2.5%-4.5% (decelerating from 7.2% in 2025), with operating profit expected to increase on restructuring savings and non-recurrence of charges, partially offset by inflation and investments.
Risks flagged
Tariff and Trade Policy Risk
“U.S. tariffs ... had a negative effect of 0.4 percent on gross margin in 2025.”
Integration Risk from Acquisitions
“Paragon 28 had a positive impact on our net sales growth of 2.5 percent in 2025. ... costs related to the acquisition of Paragon 28 and the acquisition of Monogram” · word for word
Product Discontinuation Execution Risk
“inventory and instrument charges of approximately $170 million related to certain product lines we intend to discontinue” · word for word
10 Feb 20268-K · 2.02Net sales $2.24B (+11% y/y); Adjusted diluted earnings per share $2.42 (+5% y/y); Full-year net sales $8.23B (+7% y/y)earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q4-2025 | $2.24B | +11% y/y |
| Adjusted diluted earnings per share · Q4-2025 | $2.42 | +5% y/y |
| Full-year net sales · FY2025 | $8.23B | +7% y/y |
| Full-year adjusted diluted EPS · FY2025 | $8.20 | +3% y/y |
| Operating cash flow · FY2025 | $1.70B | |
| Free cash flow · FY2025 | $1.17B | |
| Share repurchase authorization · 2026 | $1.50B |
Risks flagged
Tariff headwinds and transition to direct sales organization in U.S. may temper 2026 sales guidance
“navigating tariff headwinds; While this bold action tempers our 2026 sales guidance”
12 Jan 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen
Risks flagged
Loss of a named executive officer may signal management instability or retention challenges.
“Mark Bezjak, a named executive officer in the 2025 proxy statement, resigns effective Jan 16, 2026.” · word for word
5 Nov 202510-QZBH reported strong Q3 2025 revenue growth of 9.7% YoY and operating profit growth of 25.7% YoY, driven by volume/mix and acquisitions.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q3-2025 | $2.00B | +10% y/y |
| Net Earnings of Zimmer Biomet Holdings, Inc. · Q3-2025 | $231M | -7% y/y |
| Operating Profit · Q3-2025 | $351M | +26% y/y |
| Diluted EPS · Q3-2025 | $1.16 | -6% y/y |
| Free Cash Flow · 9M-2025 | $1.18B | +19% y/y |
| Cash and cash equivalents · 2025-09-30 | $1.29B |
Risks flagged
Integration risk from Paragon 28 acquisition
“The purchase price allocation for the Paragon 28 acquisition is preliminary as of September 30, 2025.” · word for word
Restructuring execution risk
“The 2025 Restructuring Plan is expected to result in total pre-tax restructuring charges of approximately $ 85 million by the end of 2027.” · word for word
5 Nov 20258-K · 2.02Net sales $2.00B (+10% y/y); Organic constant currency revenue growth 5; Diluted EPS $1.16; Guidance: Reported revenue growth 6.7%-7.7%; adjusted EPS $8.10-$8.30earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q3-2025 | $2.00B | +10% y/y |
| Organic constant currency revenue growth · Q3-2025 | 5.0% | |
| Diluted EPS · Q3-2025 | $1.16 | |
| Adjusted diluted EPS · Q3-2025 | $1.90 | +9% y/y |
| Net earnings · Q3-2025 | $231M | |
| Adjusted net earnings · Q3-2025 | $377M | |
| U.S. sales · United States · Q3-2025 | $1.16B | +11% y/y |
| International sales · International · Q3-2025 | $837M | +9% y/y |
| Knees sales · Knees · Q3-2025 | $792M | +6% y/y |
| Hips sales · Hips · Q3-2025 | $506M | +5% y/y |
Guidance
Reported revenue growth 6.7%-7.7%; adjusted EPS $8.10-$8.30
Maintained reported revenue growth and adjusted EPS guidance; narrowed constant currency and organic constant currency guidance.
Risks flagged
Weakness in Latin America, Emerging Markets in Europe, and non-core businesses emerged late in the quarter.
“Our strong performance in the U.S. was partially offset by weakness in Latin America, Emerging Markets in Europe and non-core businesses, which emerged late in the quarter and are being addressed.” · word for word
Zimmer Biomet Holdings, Inc. — questions
- What did Zimmer Biomet Holdings, Inc. file recently?
- 15 SEC filings in the last 12 months. Latest: 8-K on 2026-09-08 — Zimmer Biomet announced restructuring: Kevin Thornal (Group President) departing Sep 30, 2026; promotions of Gary Campbell (President, Americas), Brian Hatcher (President, Recon, S.E.T., CMFT, Neuro and Biosurgery), Bradley Kessler (Preside
Every figure on this page comes from Zimmer Biomet Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.